SUTRO BIOPHARMA, INC.STROEarnings & Financial Report
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...
STRO Q4 FY2025 Key Financial Metrics
Revenue
$11.6M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
-21.4%
SUTRO BIOPHARMA, INC. Q4 FY2025 Financial Summary
SUTRO BIOPHARMA, INC. reported revenue of $11.6M (down 21.4% YoY) for Q4 FY2025, with a net profit of N/A (up 35.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $11.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
SUTRO BIOPHARMA, INC. Annual Revenue by Year
SUTRO BIOPHARMA, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $102.5M).
SUTRO BIOPHARMA, INC. Quarterly Revenue & Net Profit History
SUTRO BIOPHARMA, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.6M | -21.4% | N/A | N/A |
| Q3 FY2025 | $9.7M | +13.8% | $-56.9M | -586.6% |
| Q2 FY2025 | $63.7M | +148.0% | $-11.5M | -18.0% |
| Q1 FY2025 | $17.4M | +33.8% | $-76.0M | -436.6% |
| Q4 FY2024 | $14.8M | -87.0% | $-72.4M | -489.2% |
| Q3 FY2024 | $8.5M | -49.7% | $-48.8M | -572.6% |
| Q2 FY2024 | $25.7M | +146.9% | $-48.0M | -186.8% |
| Q1 FY2024 | $13.0M | +2.6% | $-58.2M | -447.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.0M | $25.7M | $8.5M | $14.8M | $17.4M | $63.7M | $9.7M | $11.6M |
| YoY Growth | 2.6% | 146.9% | -49.7% | -87.0% | 33.8% | 148.0% | 13.8% | -21.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $403.4M | $489.0M | $451.8M | $387.2M | $321.4M | $262.4M | $209.7M | $173.8M |
| Liabilities | $305.4M | $336.9M | $340.6M | $342.6M | $347.2M | $294.5M | $296.9M | $306.3M |
| Equity | $98.0M | $152.2M | $111.2M | $44.6M | $-25.8M | $-32.1M | $-87.3M | $-132.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-64.7M | $9.5M | $-64.5M | $-71.7M | $-67.9M | $-44.7M | $-38.2M | $-177.2M |